Steven L. Highfill

5.3k citations

86 papers · 2.9k indexed · 1 hit paper · h-index 23

Immunology top 1%
Oncology top 2%
Molecular Biology top 10%
Hematology top 2%
Genetics top 5%

Co-authors: Crystal L. Mackall Jillian Smith Yongzhi Cui Rosandra N. Kaplan Elizabeth M. Morse Amber Giles Bruce R. Blazar Hua Zhang
Topics: CAR-T cell therapy research (62 papers)Immune Cell Function and Interaction (20 papers)Viral Infectious Diseases and Gene Expression in Insects (18 papers)
Cited by: Immunology Oncology Hematology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: United States India France

In The Last Decade

Steven L. Highfill

81 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

2014 595 citations Steven L. Highfill, Yongzhi Cui et al. profile →

Peers

Countries citing papers authored by Steven L. Highfill

Since Specialization

Citations

This map shows the geographic impact of Steven L. Highfill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven L. Highfill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven L. Highfill more than expected).

Fields of papers citing papers by Steven L. Highfill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven L. Highfill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven L. Highfill. The network helps show where Steven L. Highfill may publish in the future.

Co-authorship network of co-authors of Steven L. Highfill

This figure shows the co-authorship network connecting the top 25 collaborators of Steven L. Highfill. A scholar is included among the top collaborators of Steven L. Highfill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven L. Highfill. Steven L. Highfill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessing the impact of cell isolation method on B cell gene expression using next-generation sequencing 2025 ·Experimental Hematology ·Amanda N. Henning,(unknown),(unknown),Hong Lei,(unknown),(unknown),(unknown),Steven L. Highfill,Valeria De Giorgi	0
2	Immunophenotype of CAR T cells and apheresis products predicts response in CD22 CAR T cell trial for B cell acute lymphoblastic leukemia 2025 ·Molecular Therapy ·Alexandra Dreyzin,Lipei Shao,Yihua Cai,Kyu Lee Han,Michaela Procházková,Michael Gertz,Bonnie Yates,Rongye Shi,Kathryn A. Martin,Naomi Taylor,Steven L. Highfill,Maura O’Neill,Þorkell Andrésson,David F. Stroncek,Ping Jin,Nirali N. Shah	3
3	Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia 2025 ·Blood Advances ·Alexandra Dreyzin,Bonnie Yates,Haneen Shalabi,Sara Silbert,Hao‐Wei Wang,Constance M. Yuan,(unknown),(unknown),(unknown),(unknown),(unknown),Lauren Little,Toni Foley,Véronique Nussenblatt,Terry J. Fry,David F. Stroncek,Steven L. Highfill,Nirali N. Shah	0
4	Dendritic Cell Cancer Vaccines: Clinical Production for Cancer Immunotherapy 2025 ·Methods in molecular biology ·Hoyoung Maeng,Purevdorj B. Olkhanud,Mary Helen Black,Steven L. Highfill,David F. Stroncek,Jay A. Berzofsky	1
5	Dendritic Cell Cancer Vaccines: A Focused Review 2025 ·Methods in molecular biology ·Hoyoung Maeng,Purevdorj B. Olkhanud,M. Jane Black,Steven L. Highfill,David F. Stroncek,Jay A. Berzofsky	2
6	T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function 2024 ·ImmunoHorizons ·Sarah Underwood,Jianjian Jin,Lipei Shao,Michaela Procházková,Rongye Shi,Hannah Song,Ping Jin,Nirali N. Shah,Robert Somerville,David F. Stroncek,Steven L. Highfill	1
7	Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial 2023 ·Blood Advances ·Jennifer N. Brudno,(unknown),(unknown),Nisha Patel,Roberto Maass‐Moreno,Mark A. Ahlman,Lekha Mikkilineni,(unknown),David F. Stroncek,Steven L. Highfill,(unknown),Rashmika Patel,Stefania Pittaluga,James N. Kochenderfer	12
8	621 A phase I study of autologous activated NK cells ± rhIL15 in children and young adults with refractory solid tumors 2023 ·SHILAP Revista de lepidopterología ·(unknown),Sabina Kaczanowska,Donna Bernstein,Nan Zhang,Anh Dinh,Robert Somerville,Steven L. Highfill,David F. Stroncek,Kevin C. Conlon,Thomas A. Waldmann,Rosa Nguyen,Melinda S. Merchant,Crystal L. Mackall,Rosandra N. Kaplan	1
9	Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays 2023 ·Cytotherapy ·Jinxia Ma,Lipei Shao,(unknown),Hui Liu,Rongye Shi,Anh Dinh,Steven L. Highfill,Nan Zhang,Sandhya R. Panch,Robert Somerville,David F. Stroncek,Ping Jin	8
10	Assessment and comparison of viability assays for cellular products 2023 ·Cytotherapy ·Yihua Cai,Michaela Procházková,Yongsoo Kim,Chunjie Jiang,Jinxia Ma,(unknown),Kathryn R. Martin,Victoria C. Pham,(unknown),Steven L. Highfill,Robert Somerville,David F. Stroncek,Ping Jin	10
11	Optimizing a fully automated and closed system process for red blood cell reduction of human bone marrow products 2023 ·Cytotherapy ·(unknown),(unknown),Sarah Underwood,Jianjian Jin,(unknown),Yihua Cai,Michaela Procházková,(unknown),(unknown),Ping Jin,David F. Stroncek,Steven L. Highfill	0
12	Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation 2022 ·Journal for ImmunoTherapy of Cancer ·(unknown),John C. Molina,(unknown),(unknown),Ting Zhou,Constance M. Yuan,Hao‐Wei Wang,Maryalice Stetler‐Stevenson,Crystal L. Mackall,Terry J. Fry,Sandhya R. Panch,Steven L. Highfill,David F. Stroncek,Lauren Little,Daniel W Lee,Haneen Shalabi,Bonnie Yates,Nirali N. Shah	31
13	Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells 2022 ·Molecular Therapy — Methods & Clinical Development ·Alexandra Dreyzin,Sandhya R. Panch,Haneen Shalabi,Bonnie Yates,Steven L. Highfill,Ping Jin,David F. Stroncek,Nirali N. Shah	9
14	Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1 2022 ·Human Gene Therapy ·Richard H. Smith,(unknown),Danielle Fink,Keyvan Keyvanfar,(unknown),(unknown),(unknown),(unknown),Luigi J. Alvarado,Thomas R. Bauer,Dennis D. Hickstein,David W. Russell,Punam Malik,Johannes C.M. van der Loo,Steven L. Highfill,Douglas B. Kuhns,Mehdi Pirooznia,André Larochelle	2
15	Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence 2019 ·Clinical Cancer Research ·Sneha Ramakrishna,Steven L. Highfill,(unknown),Sang M. Nguyen,Haiyan Lei,Jack F. Shern,Haiying Qin,Ira L. Kraft,Maryalice Stetler‐Stevenson,Constance M. Yuan,Jennifer Hwang,Yang Feng,Zhongyu Zhu,Dimiter S. Dimitrov,Nirali N. Shah,Terry J. Fry	115
16	Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas 2016 ·Cancer Immunology Research ·Adrienne H. Long,Steven L. Highfill,Yongzhi Cui,Jillian Smith,Alec J. Walker,Sneha Ramakrishna,(unknown),Susana Galli,Maria Tsokos,Rimas J. Orentas,Crystal L. Mackall	258
17	Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre–metastatic Niche 2016 ·Cancer Research ·Amber Giles,Caitlin Marie Reid,(unknown),Meera Murgai,(unknown),Steven L. Highfill,Miki Kasai,Linda T. Vahdat,Crystal L. Mackall,David Lyden,Leonard H. Wexler,Rosandra N. Kaplan	117
18	Nfatc2 and Tob1 Have Non-Overlapping Function in T Cell Negative Regulation and Tumorigenesis 2014 ·PLoS ONE ·(unknown),Qing Zhou,(unknown),(unknown),David G. Coffey,Steven L. Highfill,Christoph Bucher,Ilze Matise,Herbert C. Morse,Maeve O’Sullivan,Melissa M. Schutten,Charles S. Johnson,Donald Bellgrau,Bruce R. Blazar,Jaime F. Modiano	10
19	Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia 2010 ·Blood ·Qing Zhou,Meghan E. Munger,Steven L. Highfill,Jakub Tolar,Brenda J. Weigel,Megan Riddle,Arlene H. Sharpe,Daniel A. Vallera,Miyuki Azuma,Bruce L. Levine,Carl H. June,William J. Murphy,David H. Munn,Bruce R. Blazar	230
20	Expansion of Myeloid Suppressor Cells in SHIP-Deficient Mice Represses Allogeneic T Cell Responses 2004 ·The Journal of Immunology ·Tomar Ghansah,Kim H.T. Paraiso,Steven L. Highfill,Caroline Desponts,(unknown),(unknown),(unknown),John M. Ninos,Jason Brayer,Fengdong Cheng,Eduardo M. Sotomayor,William G. Kerr	87

About Steven L. Highfill

Steven L. Highfill is a scholar working on Oncology, Immunology and Hematology, having authored 86 papers that have together received 2.9k indexed citations. Recurring topics across this work include CAR-T cell therapy research (62 papers), Immune Cell Function and Interaction (20 papers) and Viral Infectious Diseases and Gene Expression in Insects (18 papers). The work is most often cited by research in Immunology (1.7k citations), Oncology (1.6k citations) and Hematology (374 citations). Steven L. Highfill has collaborated with scholars based in United States, India and France. Frequent co-authors include Crystal L. Mackall, Jillian Smith, Yongzhi Cui, Rosandra N. Kaplan, Elizabeth M. Morse, Amber Giles, Bruce R. Blazar, Hua Zhang, Jakub Tolar and David H. Munn. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact